Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 16;10(1):16-22.
doi: 10.4253/wjge.v10.i1.16.

New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction

Affiliations

New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction

Masataka Kikuyama et al. World J Gastrointest Endosc. .

Abstract

Aim: To investigate whether an uncovered self-expandable metal stent (UCSEMS) with a large diameter could prevent recurrent biliary obstruction (RBO).

Methods: Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter (Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.

Results: Stent placement success and functional success were achieved in all patients. Two patients (5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190 (range, 164-215) d. The median survival time was 120 (range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4 (10.3%), 3 (7.9%), 2 (5.3%), 1 (2.6%), and 1 (2.6%), respectively. Migration of the stents was not observed.

Conclusion: Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration.

Keywords: Adverse event; Bile duct cancer; Ingrowth; Malignant biliary obstruction; Metal stent; Migration; Overgrowth; Pancreatic cancer; Pancreatitis; Recurrent biliary obstruction.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Authors declare no conflicts of interest for this article.

Figures

Figure 1
Figure 1
Niti-S 14 appearance with a braided structure made from nitinol, and a large diameter of 14 mm with a length of 60 or 80 mm.
Figure 2
Figure 2
Stent placement of Niti-S 14 after sphincterotomy in pancreatic cancer. A: Endoscopic view; B: Picture of endoscopic retrograde pancreatocholangiography.
Figure 3
Figure 3
Endoscopic view of the duodenal major papilla after Niti-S 14 placement. The bile duct cavity is maintained despite bile duct mucosa or tumor growth into the stent.
Figure 4
Figure 4
Kaplan-Meier analysis of stent patency. The non-RBO rates of 3, 6 and 12 mo were 100%, 91% and 78%, respectively. RBO: Recurrent biliary obstruction.
Figure 5
Figure 5
Kaplan-Meier analysis of survival. The median survival time was 120 d.

References

    1. Kozarek RA. Endoscopically placed biliary drains and stents. Am Fam Physician. 1982;26:189–192. - PubMed
    1. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340:1488–1492. - PubMed
    1. Knyrim K, Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy. 1993;25:207–212. - PubMed
    1. Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998;47:1–7. - PubMed
    1. Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc. 2003;57:178–182. - PubMed

LinkOut - more resources